Shanghai, August 19, 2019--HaiHe Biopharma, a biopharmaceutical company focusing on discovery, development and commercialization of innovative anti-tumor drugs, Shanghai Institute of Materia Medica , Chinese Academy of Science (hereinafter referred to as“SIMM”) and Jinan University jointly announced that the three Parties have reached a partnership on the AXL/FLT3 Targeted Inhibitor (Code “JND30134”) jointly developed by SIMM and Jinan University, and HaiHe Biopharma will obtain a world-wide exclusive license for the development, production and commercialization of JND30134.

“The obtaining of a world-wide exclusive license for JND30134 by HaiHe Biopharma is another milestone in its development of innovative anti-tumor drugs. The early data of JND30134 indicate that it has significant anti-tumor activity both in vivo and in vitro. Moreover, its activity against AXL, FLT3 and other frontier targets shows a vast space of application covering broad anti-tumor spectrum. JND30134 will become an important complement to HaiHe Biopharma’s existing anti-tumor product pipeline and help realize our vision of satisfying unmet clinical needs and benefiting cancer patients. HaiHe Biopharma will give full play to its research and development capability of original innovative drugs, and sincerely cooperate with first-class research institutions and top universities such as Shanghai Institute of Materia Medica and Jinan University to bring more safe and effective innovative drugs to the global market. ” said Dr. Dong Ruiping, CEO of HaiHe Biopharma.

JND30134 is a small molecule kinase targeting inhibitor, which can synchronously inhibit the enzyme activity of AXL, FLT3 and NTRK kinase, and has the dual functions of targeting tumor cells and tumor immune microenvironment. It has significant anti-tumor activity both in vitro and in vivo, with a wide range of potential treatment space. In addition, JND30134 has good metabolic characteristics and a large potential safety window. The compound was jointly developed by Shanghai Institute of Materia Medica and Jinan University and is currently in undergoing the systematic preclinical study, with patent applications filed both at home and abroad.

Haihe Biopharma is an innovation-driven biotechnology company in China focusing on the discovery, development, production and commercialization of innovative anti-tumor drugs. Haihe brings life-saving therapies to cancer patients worldwide. It also has a research and management team with a global perspective, and is proactively mapping out the international development of innovative drugs. The Company currently has thirteen key drug candidates. As of today, Haihe Biopharma has received 21 IND or clinical trial approvals in four countries and regions. 

Shanghai Institute of Materia Medica (hereafter referred as SIMM), Chinese Academy of Sciences (hereafter referred as CAS), has the longest history as a comprehensive research institution for drug discovery in China. SIMM was evolved from Peking Institute of Materia Medica, Academia Sinica, founded in 1932 by Professor Chenggu Zhao (T. Q. Chou). It was relocated to Wukang Road, Shanghai in 1933, then to Yueyang Road in 1953, and settled down in Zhang Jiang Hi-Tech Park, Pudong New District in 2003.  In line with the mission of “Discovering new drugs to relieve patients suffering from various diseases”, SIMM has developed and commercialized over 100 new drugs in the past 80 years. Among them, a number of innovative drugs, such as Artemether, Dimercaptosuccinic acid, and Huperzine A, etc., have gained domestic and abroad recognitions. Recent years SIMM have witnessed the development of some novel drugs, including Depsides salts, a modern Traditional Chinese Medicine (TCM), and Antofloxacin Hydrochloride, a novel fluoroquinolone antibacterial agent. Currently, SIMM has a number of candidates in clinical stages.  Since the implementation of the Knowledge Innovation Program of CAS, developing novel drugs has become a paramount research focus of SIMM in recent years. In line with frontiers in life sciences and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such cancers, cardio-cerebrovascular diseases, neuropsychiatric diseases, metabolic diseases, autoimmune diseases, and infectious diseases. SIMM also pays attention to the development of modern traditional Chinese Medicine (TCM).  Through several generations’ efforts, SIMM has become one of the leading interdisciplinary research centers in China. It is recognized worldwide by its outstanding achievements and distinguished research teams. 

Please visit the company website for more information: http://www.simm.cas.cn

Jinan University is a key comprehensive university which is listed in '211 Project' and jointly constructed by Overseas Chinese Affairs Office of the State Council, Ministry of Education of the People's Republic of China and Guangdong Province. As the Paramount School of Overseas Chinese Students, JNU is always upholding the faith of diffusing the knowledge and caring for Overseas Chinese, the motto of loyalty, sincerity, integrity and respect and the policy of international orientation especially towards Hong Kong, Macao and Taiwan. We remain dedicated to widely recruiting students from home and abroad, seeking excellent teachers and equipping JNU with advanced teaching conditions to popularize Chinese traditional culture and cultivate various talents for the society. Jinan University carries out the mission of continuing distingue spirits for past sages along with establishing best disciplines as well as the a top university for all future generations so that it be entitled with one of the prestigious universities in China or even in Asia.

Please visit the company website for more information:https://www.jnu.edu.cn/